장마감
로그인 회원가입
PRAX
PRAX
Praxis Precision Medicines Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$315.80
-9.50 ▼ -2.92%
🌙 7월 27일 4:10 PM ET (한국 7/28 05:10)
$315.80
+0.00 +0.00%

프락시스 정밀의학(PRAX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$8.8B
스몰캡
P/E
-
배당수익률
없음
52주 위치
85%
저점 +749% · 고점 -14%
애널리스트
적극 매수
B-
Fundamental health
vs. 미분류 중형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 44%
밸류에이션
데이터 부족
재무 안정
Top 45%
Index RUTP/E -EPS (ttm) -13.38Insider Own 6.32%Shs Outstand 27.9MPerf Week 3.73%
Market Cap 8.80BForward P/E -EPS next Y 31.89%Insider Trans -0.65%Shs Float 26.1MPerf Month -3.68%
Enterprise Value 8.02BPEG -EPS next Q -3.67Inst Own 109.28%Short Float 14.41%Perf Quarter -8.42%
Income -0.33BP/S -EPS this Y -13.31%Inst Trans 5.8%Short Ratio 7.69Perf Half Y 1.31%
Sales 0.00BP/B 6.24EPS next 5Y -ROA -33.68%Short Interest 3.76MPerf YTD 7.15%
Book/sh 50.61P/C 11.19EPS past 3/5Y 42.16% 13.34%ROE -35.32%52W High -13.84% ($366.52)Perf Year 433.27%
Cash/sh 28.22P/FCF -Sales past 3/5Y -ROIC -23.16%52W Low 749.15% ($37.19)Perf 3Y 2332.22%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -24.9%Gross Margin -Volatility(W/M) 5.13% 6.41%Perf 5Y 34.1%
Dividend TTM -EV/Sales -Sales Y/Y TTM -100%Oper. Margin -ATR (14) 18.5Perf 10Y -
Dividend Ex-Date -Quick Ratio 15.88EPS Q/Q 2.63%Profit Margin -RSI (14) 50.39Recom 1.37
Dividend Gr. 3/5Y -Current Ratio 15.88Sales Q/Q -SMA20 -1.82% ($321.65)Beta 2.79Target Price $604.84
Payout -Debt/Eq 0Earnings 2026/5/7SMA50 1.87% ($310)Rel Volume 0.61Prev Close $325.3
Employees 168LT Debt/Eq 0EPS/Sales Surpr. 10.85% -SMA200 12.99% ($279.49)Avg Volume(3M) 0.49MPrice $315.8
IPO 2020/10/16Option/Short Yes/YesTrades 9443Volume 296,033Change -2.92%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-93M (YoY -34%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Praxis Precision Medicines Inc (PRAX) Investment Analysis

What kind of company is Praxis Precision Medicines Inc?

프락시스 정밀의학(PRAX)
Healthcare · Biotechnology
#1023 by Market Cap — Mid-Cap

🧠 This clinical-stage biotech company develops therapeutics for central nervous system (CNS) disorders. Leveraging insights from hereditary epilepsy research, the company develops treatments for conditions related to neural excitation-inhibition imbalance, such as epilepsy and movement disorders. As a neuroscience healthcare stock, its share price is largely driven by the approval and clinical progress of its late-stage candidates.

Learn more about Praxis Precision Medicines Inc →
Market Cap
$8.8B
Approx. KRW 12.1 trillion
⚖️ 3% of Samsung Electronics
Market Cap Rank1023
Employees168people
IPO2020/10/16
Current Price$315.80 ≈ 432,646원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS +10.8%
🔔 Earnings release 2026년 2월 19일 (목) · 장 시작 전 EPS -12.0% 매출 -100.0%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-35.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-33.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-23.2%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.00
✓ Very low debt
My positionTop 5%
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
15.88
✓ 우수
My positionTop 25%
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
15.88
✓ 우수
My positionTop 25%
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$604.84
현재가 대비 +91.5%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+31.9%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
+0.5%
평균 서프라이즈
2026.05.07
상회
실적 $-3.20 · 예상 $-3.68 +13.0%
2026.02.19
하회
실적 $-3.50 · 예상 $-3.13 -12.0%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-13.3%
평균
My positionMid-range
Low range Average High range
미분류 중형주 Median 7.3% · Bottom 33%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+31.9%
양호
My positionMid-range
Low range Average High range
미분류 중형주 Median 15.6% · Top 45%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+42.2%
우수
My positionTop 25%
Low range Average High range
미분류 중형주 Median 18.2% · Top 20%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+13.3%
양호
My positionMid-range
Low range Average High range
미분류 중형주 Median 6.4% · Top 43%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -34%p below the market
PRAX +34.1% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-34.2%p
Significantly behind the market
vs Health Care (XLV)
+9.6%p
slightly ahead of the sector average
1-year basis
vs S&P 500
+417.3%p
well ahead of the market
vs Health Care (XLV)
+413.5%p
well ahead of the sector average
Rank among peers
5-year return Lower-Mid (lower 44%) Based on 64 peers
1-year return Top among peers Based on 76 peers
Current position within 52-week range
Low (-749.1%p) High (-13.8%p)
Current price is 749.1% above the 52-week low and 13.8% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-32.5%
Annualized volatility
67.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $315.80 below the midline ($321.70). Normal downward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD 2.618 · Signal 3.309 · Hist -0.691. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 50.4 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 37.9.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
6.24x
✓ Cheap
My positionMid-range
Low range Average High range
Biotechnology 중형주 median 6.81x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
Analyst target price (reference)
$604.84 vs. current price +91.5%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 중형주

Who owns it?

Ownership is broadly stable
Insider modest net selling -0.7% · Institutional net buying +5.8% · Short interest elevated 14.4%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-0.7%
Insiders net selling
🏦 Institutions (funds & investors)
+5.8%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 109.3%
Institution-led, stable structure
Healthcare 중형주 Median 89.4%
🧑‍💼 Insiders 6.3%
Meaningful insider stake
Healthcare 중형주 Median 9.4%
👤 Retail investors (estimated) 0.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
14.4%
Somewhat high
Healthcare 중형주 Median 11.3%
Past 90 days Little change
Short interest days to cover
7.7 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 27.9M주
Float (tradable shares) 26.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding PRAX

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
PRAX PRAX This Stock
$8.8B- 6.2 -35.32% - -2.9%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 프락시스 정밀의학(PRAX)?

프락시스 정밀의학(PRAX) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of PRAX?

The market cap of PRAX is approximately $8.8B, ranking 1,023 within its sector.

What is the 52-week high and low for PRAX?

PRAX has recorded a 52-week high of $366.52 and a low of $37.19.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.